Earlier this year, Andrea James – the IR Impact Award-winning former investor relations lead at Axon – talked to us about taking a sabbatical from investor relations as she sought a new role. Having taken time to herself, then taken time think about what her next move might look like, she manifested a CFO position at a small cap. That small cap is Nasdaq-listed precision diagnostics firm Oncocyte.
Here James talks to IR Impact about the skills you need to make the move from IR to CFO, what she looks for from her advisers and why stock-picking and finance . . .
Log in FOR FREE to access this content
Log in or create your free My IR – Essentials account to:
- Access 50+ deep dives and best practice reports
- View 100+ news analyses and our exclusive CFO series
- Instantly benchmark your IR program with our new tool
- Save favorites and get tailored content delivered to your dashboard
- 10% off all IR forums!
Join now to make a real impact in your organization.
